1. Home
  2. CYTK vs FRHC Comparison

CYTK vs FRHC Comparison

Compare CYTK & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$78.68

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Logo Freedom Holding Corp.

FRHC

Freedom Holding Corp.

HOLD

Current Price

$144.27

Market Cap

8.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
FRHC
Founded
1997
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
8.6B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
CYTK
FRHC
Price
$78.68
$144.27
Analyst Decision
Strong Buy
Analyst Count
19
0
Target Price
$89.26
N/A
AVG Volume (30 Days)
1.7M
180.9K
Earning Date
05-05-2026
06-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.29
EPS
N/A
2.51
Revenue
$13,368,000.00
$2,191,291,000.00
Revenue This Year
$7.37
N/A
Revenue Next Year
$310.19
N/A
P/E Ratio
N/A
$53.35
Revenue Growth
N/A
6.86
52 Week Low
$31.99
$107.98
52 Week High
$80.20
$194.01

Technical Indicators

Market Signals
Indicator
CYTK
FRHC
Relative Strength Index (RSI) 62.37 49.55
Support Level $59.07 $133.76
Resistance Level $79.66 $150.54
Average True Range (ATR) 3.20 8.97
MACD 0.51 -0.97
Stochastic Oscillator 83.65 36.02

Price Performance

Historical Comparison
CYTK
FRHC

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About FRHC Freedom Holding Corp.

Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.

Share on Social Networks: